- VY7523 clinical data readout on track for Q4 2026 and VY1706 dosing expected in the next few months pending enrollment - - Neurocrine Biosciences partnered Friedreich’s ataxia gene therapy program expected to enter
LEXINGTON, Mass., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced two poster
- Robin Swartz, Voyager’s Chief Business and Operating Officer, appointed President, effective immediately; expected to succeed Alfred W. Sandrock, Jr., M.D., Ph.D., as CEO in Q1 2027 - - Dr. Sandrock expected to
LEXINGTON, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that the company
- VY7523 clinical data and VY1706 clinical entry, both in Alzheimer’s, expected Q4 2026 - - Ended Q2 2026 with cash position of $149 million, runway into 2028 - LEXINGTON, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) --
- Data presented as Developing Topics poster at AAIC 2026 - LEXINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to leveraging genetics to
LEXINGTON, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced a Developing
LEXINGTON, Mass., June 11, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that Alfred W.
- Dosing of adults with early Alzheimer's disease in clinical trial expected H2 2026 - - Comprehensive preclinical program showed compelling pharmacology and safety profile for VY1706 - - VY1706 uses an IV-delivered,
Equity Insider News CommentaryIssued on behalf of Avaí Bio, Inc.Joint venture with Austrianova advances the production of cells that produce the longevity protein α-Klotho from encapsulated cells; latest data to be
- VY1706 IND application process on track for Q2 2026; clinical entry expected H2 2026 - - Data from eight ASGCT presentations highlight Voyager's continued innovation in gene therapy - LEXINGTON, Mass., May 13, 2026
- Late-breaking oral presentation: IV delivery of VY1706, a CNS penetrant AAV gene therapy for AD, demonstrates compelling pharmacology and safety in a 3-month GLP toxicology study in NHPs - - Additional data
- Transformative year for tau in AD: VY1706 clinical entry and VY7523 clinical data anticipated H2 2026 - - Validating brain-targeted capsids in humans: expect two I.V.-delivered neuro gene therapies to enter clinic H2
LEXINGTON, Mass., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that the company
